Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ERLEADA vs ANDROID-F
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Erleada (apalutamide) is an androgen receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR, preventing AR nuclear translocation, DNA binding, and transcription of AR target genes. It also inhibits AR-mediated tumor growth and reduces prostate-specific antigen (PSA) levels.
Fingolimod is a sphingosine 1-phosphate receptor modulator that sequesters lymphocytes in lymph nodes, reducing central nervous system immune cell infiltration.
Treatment of non-metastatic castration-resistant prostate cancer (nm CRPC),Treatment of metastatic castration-sensitive prostate cancer (m CSPC)
Relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease
240 mg orally once daily on an empty stomach, taken at least 1 hour before or 2 hours after a meal. Swallow tablets whole.
Adults: 1 tablet (methyltestosterone 2.5 mg, ethinyl estradiol 0.025 mg) orally once daily, with food.
Terminal elimination half-life is approximately 20 hours (range 16-24 hours) at steady state, supporting once-daily dosing.
2.5-3.5 hours (terminal half-life); oral administration may require multiple daily doses for stable levels.
Primarily metabolized by CYP2C8 and CYP3A4 to form active metabolites (N-desmethyl apalutamide). It is also a strong inducer of CYP3A4 and CYP2C9, and has moderate effects on CYP2C19 and UGTs.
Metabolized primarily by CYP4F2, with minor contributions from CYP2D6, CYP2E1, CYP3A4, and CYP1A2. Undergoes biotransformation to an inactive metabolite.
Fecal (87.4%) as unchanged drug and metabolites; renal (2.4%) as unchanged drug.
Primarily renal (90% as glucuronide and sulfate conjugates, 10% unchanged); small amount biliary/fecal.
Highly protein bound (97%) primarily to albumin and α1-acid glycoprotein (AAG).
97-99% bound to sex hormone-binding globulin (SHBG) and albumin.
Apparent volume of distribution (Vd/F) is approximately 157 L (about 2.2 L/kg for a 70 kg adult), indicating extensive extravascular distribution.
0.5-0.8 L/kg; reflects distribution into muscle, liver, and reproductive tissues.
Oral bioavailability is not determined due to lack of intravenous formulation; after oral administration, absorption is rapid with Tmax of 2 hours under fasting conditions; food increases Cmax by 2- to 4-fold and AUC by 2-fold.
Oral: 3-6% (extensive first-pass metabolism); IM: 100%.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease; use with caution.
GFR 10-50 m L/min: reduce dose by 50%. GFR <10 m L/min: avoid use.
Mild hepatic impairment (Child-Pugh A): no dose adjustment. Moderate (Child-Pugh B): reduce dose to 120 mg once daily. Severe (Child-Pugh C): not recommended.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: avoid use. Child-Pugh C: contraindicated.
Safety and efficacy not established in pediatric patients; no specific pediatric dosing available.
Not recommended for use in children due to risk of premature epiphyseal closure and virilization.
No specific dose adjustment required based on age alone; monitor for adverse effects (e.g., falls, hypertension) more frequently in elderly patients.
Use with caution; consider lower starting dose due to increased risk of fluid retention, hypertension, and prostatic hypertrophy in males.
No boxed warning.
Risk of bradyarrhythmia and atrioventricular block, requiring first-dose monitoring for 6 hours. Fatal infections, including opportunistic infections, have occurred. Macular edema has been reported.
Seizure: Increased risk, especially in patients with predisposing factors; discontinue if seizure occurs.,Falls and fractures: Increased incidence in clinical trials; assess fall and fracture risk.,Cardiovascular effects: Hypertension, especially in patients with pre-existing cardiovascular disease.,Thyroid dysfunction: Monitor thyroid function tests periodically.,Hypercholesterolemia: Monitor lipid profile and manage accordingly.,Hypersensitivity reactions: Including angioedema; discontinue if severe.
May cause bradycardia and AV block; monitor heart rate after first dose. Increased risk of infections, including herpes viruses and cryptococcal meningitis. Macular edema, especially in patients with diabetes or uveitis. Posterior reversible encephalopathy syndrome (PRES). Respiratory effects, including decreased FEV1 and DLCO. Hepatic injury; monitor liver enzymes.
Pregnancy: Apalutamide can cause fetal harm and is contraindicated in pregnant women.,Severe hypersensitivity to apalutamide or any component of the formulation.
Recent myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure, history of Mobitz type II 2nd or 3rd degree AV block, sick sinus syndrome unless pacemaker is present, or severe untreated sleep apnea.
Grapefruit and grapefruit juice may increase apalutamide concentrations; avoid consumption. No other food interactions known.
No significant food interactions reported. Avoid excessive alcohol consumption due to hepatotoxic effects.
Risk Category X. ERLEADA (apalutamide) can cause fetal harm when administered to a pregnant woman. Nonclinical studies have demonstrated teratogenicity, including skeletal abnormalities and reduced fetal weight, at exposures below the recommended human dose. As male patients exposed to ERLEADA may father a child, a pregnancy test should be conducted for female partners of reproductive potential prior to initiating therapy. Advise male patients to use effective contraception during treatment and for 3 months after the last dose. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to the fetus.
ANDROID-F contains methyltestosterone, a synthetic androgen. Androgens are teratogenic in humans. In first trimester: masculinization of female fetus, including clitoromegaly, labial fusion, and urogenital sinus abnormalities. Second and third trimesters: continued virilization of female fetus; no increased risk of malformations in male fetuses. Contraindicated in pregnancy.
No data available on the presence of apalutamide in human milk, its effects on the breastfed infant, or its effects on milk production. Because of the potential for serious adverse reactions in breastfed infants from ERLEADA, advise women not to breastfeed during treatment and for at least 3 months after the last dose. The milk-to-plasma ratio is unknown.
Methyltestosterone is excreted in breast milk. No specific M/P ratio available. May cause virilization in female infants and precocious development in male infants. Breastfeeding is contraindicated during therapy.
ERLEADA is contraindicated in pregnancy. No dose adjustment is recommended for non-pregnant patients; however, due to the risk of fetal harm, use is not recommended during pregnancy. Pharmacokinetic changes of apalutamide specifically during pregnancy have not been studied, and no dose adjustments are recommended as the drug is not used in pregnant women.
ANDROID-F is contraindicated in pregnancy; no dosing recommendations for use in pregnancy. No established dose adjustments exist as the drug should not be administered.
ERLEADA (apalutamide) requires concomitant use with a Gn RH analog or bilateral orchiectomy. Monitor for hypertension, hypothyroidism, and hypercholesterolemia. Falls and fractures are increased; assess fracture risk. Use with caution in patients at risk for seizures, as clinical seizures occurred in 0.2% of patients. Dose adjustment for CYP3A4 substrates with narrow therapeutic index.
Android-F is a brand of methyltestosterone, an androgen used primarily for male hypogonadism. Monitor liver function due to potential hepatotoxicity. Avoid in males with breast or prostate cancer. Use with caution in older patients due to increased risk of prostatic hypertrophy. May suppress clotting factors II, V, VII, and X.
Take ERLEADA once daily at the same time each day, with or without food. Swallow tablets whole; do not crush or chew.,Use effective contraception during treatment and for 3 months after last dose. ERLEADA can cause fetal harm.,Report any signs of infection, falls, fractures, or seizures immediately. Risk of falls and fractures is increased.,Blood pressure, thyroid function, and cholesterol levels will be monitored regularly. Report symptoms of hypothyroidism like fatigue or cold intolerance.,Avoid grapefruit, grapefruit juice, or products containing grapefruit while on ERLEADA.
Take exactly as prescribed; do not increase dose or frequency.,Report any signs of liver problems (yellowing eyes/skin, dark urine, persistent nausea) immediately.,Women should report hoarseness, acne, or menstrual changes.,Men should report frequent or persistent erections, or breast swelling/tenderness.,May cause decreased sperm count in men; discuss family planning.,Avoid concurrent use with other medications without consulting doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ERLEADA vs ANDROID-F, answered by our medical review team.
ERLEADA is a Androgen Receptor Inhibitor Antineoplastic that works by Erleada (apalutamide) is an androgen receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR, preventing AR nuclear translocation, DNA binding, and transcription of AR target genes. It also inhibits AR-mediated tumor growth and reduces prostate-specific antigen (PSA) levels.. ANDROID-F is a Androgen/Estrogen Combination that works by Fingolimod is a sphingosine 1-phosphate receptor modulator that sequesters lymphocytes in lymph nodes, reducing central nervous system immune cell infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ERLEADA and ANDROID-F depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ERLEADA is: 240 mg orally once daily on an empty stomach, taken at least 1 hour before or 2 hours after a meal. Swallow tablets whole.. The standard adult dose of ANDROID-F is: Adults: 1 tablet (methyltestosterone 2.5 mg, ethinyl estradiol 0.025 mg) orally once daily, with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ERLEADA and ANDROID-F in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ERLEADA is classified as Category C. Risk Category X. ERLEADA (apalutamide) can cause fetal harm when administered to a pregnant woman. Nonclinical studies have demonstrated teratogenicity, including skeletal abnormal. ANDROID-F is classified as Category C. ANDROID-F contains methyltestosterone, a synthetic androgen. Androgens are teratogenic in humans. In first trimester: masculinization of female fetus, including clitoromegaly, labi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.